MedWatch

Analyst: It could give Lundbeck a boost

New data on a Parkinsons drug that earned its developer, Lundbeck, more than a billion kroner last year could give the Danish company a fresh boost, says Alm. Brand analyst Michael Friis Jørgensen.

Foto: Lundbeck PR

Recently published data from a new study of Lundbeck and Teva’s Azilect could help boost sales of the Parkinson’s drug, says analyst Michael Friis Jørgensen from Alm. Brand Markets.

“It is difficult to offer an exact number, but on a whole it is of course positive. Whether it will give the same kind of boost that the Adagio studies did – I do not think so. It is an important product for Lundbeck, so it is positive for the company to get these data. Growth rates for the product have started declining following a very strong period,” he says and adds about the Adagio study:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier